Amylin Pharmaceuticals, Inc. announced the availability of the SymlinPen 120 and the SymlinPen 60 pen-injector devices for administering SYMLIN (pramlintide acetate) injection. These new pre-filled pen-injector devices feature simple, fixed dosing to improve mealtime glucose control.
"Symlin offers enhanced blood glucose control with potential weight loss for patients with diabetes using mealtime insulin, enabling them to do more to manage their diabetes," said Daniel M. Bradbury, president and CEO, Amylin Pharmaceuticals. "The convenience of the new SymlinPen with simple, fixed dosing will make it easier for these patients using multiple daily injections to start and stay with Symlin."
SymlinPen 120 features fixed dosing to deliver 60 or 120 micrograms of Symlin per dose. SymlinPen 60 features fixed dosing to deliver 15, 30, 45, or 60 micrograms of Symlin per dose. Both pen-injector devices can be conveniently stored at room temperature not to exceed 86 degrees F (30 degrees C) after first use.
Symlin is an injectable medicine used to control blood sugar after meals in adults with type 2 or type 1 diabetes who take mealtime insulin. Symlin is the first and only amylin mimetic for use in patients with diabetes treated with mealtime insulin. Symlin is a synthetic analog of human amylin, a naturally occurring hormone that is made in the beta cells of the pancreas, the same cells that make insulin. In patients with type 2 diabetes who use insulin, and in patients with type 1 diabetes, those cells in the pancreas are either damaged or destroyed, resulting in reduced secretion of both insulin and amylin after meals. The use of Symlin contributes to glucose control after meals.
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over 1,900 employees nationwide.